Choose language / Korean

EN / 한
Bull/Bear Index 45.9/100
global ▲ Bull Impact 75/100 금융감독원 전자공시(DART) 8h ago Read original ↗

DXVX Signs 10.3 Billion KRW Healthcare Product Supply Contract in China

DXVX has entered into a supply contract worth 10.3 billion KRW for healthcare products with Hangzhou Guangcheng Enterprise Management Consulting Co., Ltd. This contract represents 22.11% of the company's recent revenue.

How this call is verified

The ▲ Bullish call is auto-verified against the actual KOSPI price in ~16h.

Bar: KOSPI ±0.9% within 24h · every verdict lands on the public ledger

AI comment — why bullish

DXVX has announced a significant supply contract for healthcare products to China, valued at approximately 10.3 billion KRW. This figure represents a substantial 22.11% of the company's most recent reported revenue, indicating a material impact on its financial performance. The counterparty, Hangzhou Guangcheng Enterprise Management Consulting Co., Ltd., operates within the bio-health industry, suggesting a strategic alignment. Investors should monitor the execution of this contract and any further details regarding the specific products and timelines. The success of this deal could signal DXVX's growing presence and capabilities within the Chinese market.

Key takeaway

"DXVX Signs 10.3 Billion KRW Healthcare Product Supply Contract in China" — BullBear's AI rates this story as a bullish (positive) signal for markets, with a market-impact score of 75 out of 100. DXVX has entered into a supply contract worth 10.3 billion KRW for healthcare products with Hangzhou Guangcheng Enterprise Management Consulting Co., Ltd. This contract represents 22.11% of the company's recent revenue. DXVX has announced a significant supply contract for healthcare products to China, valued at approximately 10.3 billion KRW. This figure represents a substantial 22.11% of the company's most recent reported revenue, indicating a material impact on its financial performance. The counterparty, Hangzhou Guangcheng Enterprise Management Consulting Co., Ltd., operates within the bio-health industry, suggesting a strategic alignment. Investors should monitor the execution of this contract and any further details regarding the specific products and timelines. The success of this deal could signal DXVX's growing presence and capabilities within the Chinese market. That score reflects how strongly the story is likely to move Bitcoin, US equities, the dollar, and gold, and near-duplicate coverage of the same event is clustered so only the representative article is scored. Reported by 금융감독원 전자공시(DART) on August 21, 2026. The call is verified against the actual 24-hour price move on BullBear's public conviction ledger.

Catch the next bull catalyst

Telegram alerts when our AI scores a story 80+/100 impact (~1-3 per day, no spam). Verified 30d hit rate 44.4%.

Join Telegram channel

📡 Tomorrow's Watch